LPL Receptor Inhibitor

LPL Receptor Inhibitors (42):

Cat. No.	Product Name	Effect	Purity

HY-D1005

Poloxamer 407 (F127)	Inhibitor
Poloxamer 407 (F127) is a nonionic surfactant that is 100% active and relatively non-toxic to cells at low concentrations, and frequently used with dye AM esters such as Indo-1 AM, Fura-2 AM, Calcein AM, Fluo-3 AM, Fluo-4 AM, Quest Fluo-8 AM and Quest Rhod-4 AM, etc. to improve their water solubility. Poloxamer 407 is also a lipoprotein lipase inhibitor.

HY-P991310

Lpathomab	Inhibitor
Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-16040

AM095 free acid	Inhibitor	99.02%
AM095 (free acid) is a potent LPA1 receptor antagonist with IC₅₀ values of 0.98 and 0.73 μM for recombinant human or mouse LPA1 respectively.

HY-149004

SLF1081851	Inhibitor	98.02%
SLF1081851 is a Spns2 inhibitor, inhibits S1P release (IC₅₀=1.93 μM). SLF1081851 plays a key role in development and immune system.

HY-116147

Ceranib-2	Inhibitor	99.25%
Ceranib-2 is a potent and nonlipid ceramidase inhibitor that inhibits cellular ceramidase activity with an IC₅₀ of 28 μM in SKOV3 cells. Ceranib-2 induces the accumulation of multiple ceramide species, decreases levels of sphingosine and sphingosine-1-phosphate (S1P), and induces cell apoptosis. Anticancer activity.

HY-18075

LPA2 antagonist 1	Inhibitor	98.63%
LPA2 antagonist 1 is a LPA2 antagonist with an IC₅₀ of 17 nM.

HY-100619A

BMS-986020 sodium	Inhibitor	99.88%
BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist. BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC₅₀s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively. BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF).

HY-126145

S1PR1 modulator 1	Inhibitor	99.52%
S1PR1 modulator 1 is a selective S1PR1 inhibitor, with a pIC₅₀ of 7.6, with >40- and >80-fold selectivity, over the other S1PR isoforms S1PR2/3/4.

HY-162655

SLF80821178	Inhibitor	99.70%
SLF80821178 is a potent and orally active inhibitor of Sphingosine-1-Phosphate Transporter (Spns2). SLF80821178 inhibits S1P release with an IC₅₀ of 51 nM in HeLa cells and a T_1/2 of 2.4 h in mouse.

HY-150254A

SLB1122168 formic	Inhibitor	99.91%
SLB1122168 formic is a potent Spns2-mediated S1P release inhibitor with an IC₅₀ of 94 nM.

HY-N2553

4-Deoxypyridoxine 5'-phosphate	Inhibitor	≥98.0%
4-Deoxypyridoxine 5'-phosphate is a Pyridoxal 5'-phosphate analogue and a sphingosine 1-phosphate (S1P) inhibitor. 4-Deoxypyridoxine 5'-phosphate inhibits ornithine decarboxylase activity with a K_i of 60 μM. 4-Deoxypyridoxine 5'-phosphate is a competitive inhibitor of the activation of glutamate apodecarboxylase by Pyridoxal 5'-phosphate (K_i of 0.27 μM) and strongly inhibits glutamate-dependent labeling of glutamate decarboxylase.

HY-14113

2-Acetyl-4-tetrahydroxybutyl imidazole	Inhibitor
2-Acetyl-5-tetrahydroxybutyl imidazole is a potent sphingosine-1-phosphate (S1P) lyase inhibitor in vivo.

HY-139094

A6770	Inhibitor	≥99.0%
A6770 is an orally active, potent sphingosine 1-phosphate (S1P) lyase (S1PL) inhibitor. A6770 is phosphorylated and the phosphorylated form directly inhibits S1P lyased.A6770, a potential key metabolite of THI, induces a [³H]dhS1P increase.

HY-P99318

Sonepcizumab	Inhibitor
Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC).

HY-158783

SACLAC	Inhibitor	99.70%
SACLAC, a Ceramide analog, is a potent and covalent acid ceramidase (ASAH1; AC) inhibitor with a K_i of 97.1 nM. SACLAC effectively blocks AC activity and induces a decrease in sphingosine 1-phosphate (S1P) and total ceramide levels. SACLAC reduces the levels of splicing factor SF3B1 and alternative Mcl-1 mRNA splicing, increases pro-apoptotic Mcl-1S levels to induce apoptosis in acute myeloid leukemia (AML) cells. SACLAC reduces the leukemic burden in human AML xenograft mouse models.

HY-RS12394

S1PR2 Human Pre-designed siRNA Set A	Inhibitor
S1PR2 Human Pre-designed siRNA Set A contains three designed siRNAs for S1PR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-150254

SLB1122168	Inhibitor
SLB1122168 is a potent Spns2-mediated S1P release inhibitor with an IC₅₀ of 94 nM.

HY-14370

LX2931	Inhibitor	98.31%
LX2931 is an inhibitor of Sphingosine 1-Phosphate Lyase (S1PL). LX2931 works by increasing levels of S1P inside and outside the cell. The decrease in S1PL activity leads to a significant increase in S1P content in tissues, especially in lymphoid tissues which may lead to a restricted exodus of lymphocytes from secondary immune tissues, resulting in lymphocytopenic and immunosuppressive effects in the peripheral circulation. LX2931 can be used in research for the treatment of autoimmune diseases, especially rheumatoid arthritis.

HY-RS12403

S1PR5 Human Pre-designed siRNA Set A	Inhibitor
S1PR5 Human Pre-designed siRNA Set A contains three designed siRNAs for S1PR5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS12391

S1PR1 Human Pre-designed siRNA Set A	Inhibitor
S1PR1 Human Pre-designed siRNA Set A contains three designed siRNAs for S1PR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Name
Email *

	Sorry, but the email address you supplied was invalid.